Several immunosuppressed mouse models have been used in preclinical stroke research, most prominent: (a) pharmacological immunosuppression with calcineurin inhibitory drugs (e.g., tacrolimus) that block the development and proliferation of T cells; (b) genetically deficient mice that lack recombination activating gene 2 protein (Rag2–/–) required for the generation of mature B and T lymphocytes; and (c) NOD scid gamma (NSG) mice that lack mature T and B lymphocytes, natural killer (NK) cells and have deficiencies in multiple cytokine signalling and innate immunity (11, 12). Here, RAG2 is linked to stroke disorder.